检索结果-南通市图书馆

fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial

引用

Cancer Biology & Medicine 2022年第7期19卷 1089-1099页

作者： Jingjing Wu Fenghua Gao Wenhua Wang Xudong Zhang Meng Dong Lei Zhang Xin Li Ling Li Zhenchang Sun Xinhua Wang Xiaorui Fu Linan Zhu Mengjie Ding Songtao Niu Zhaoming Li Yu Chang Feifei Nan Jiaqian Yan Hui Yu Xiaolong Wu Zhiyuan Zhou Jieming Zhang Mingzhi Zhang Cancer Research Institute Department of OncologyThe First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052HenanChina

Objective:This study aimed to evaluate the safety,efficacy,and feasibility of the rituximab,fotemustine,pemetrexed,and dexamethasone(R-FPD)regimen followed by whole-brain radiotherapy(WBRT)for patients with primary central nervous system lymphoma(PCNSL).Methods:A prospective,single-center phase II clinical trial was *** with PCNSL newly diagnosed at the First Affiliated Hospital of Zhengzhou University between July 2018 and July 2020 were *** R-FPD regimen consisted of rituximab(375 mg/m2 *** D0),fotemustine(100 mg/m2 *** D1),pemetrexed(600 mg/m2 *** D1),and dexamethasone(40 mg *** D1-5).Patients 60 years or younger who showed a complete response(CR)were treated with 23.4 Gy of WBRT after the end of chemotherapy;those older than 60 years with CR were treated with a wait-and-see approach;and those who did not show CR after the 4th cycle of chemotherapy were given salvage WBRT 30 Gy+local tumor field irradiation up to 45 Gy,regardless of ***:A total of 30 patients were *** 2 cycles,the objective response rate(ORR)was 96.5%(28/29,1 CR,27 PR,0 SD,and 1 PD).After 4 cycles,the ORR was 73.1%(19/26,11 CR,8 PR,4 SD,and 3 PD).After WBRT,the ORR was 90.9%(10/11,7 CR,3 PR,and 1 SD).The grade III and IV toxicity responses were mainly leukopenia(20.0%),thrombocytopenia(23.3%),and anemia(10.0%).Conclusions:fotemustine-based therapy in combination with rituximab chemotherapy followed by WBRT can improve outcomes,providing ORR benefits and favorable tolerability in patients newly diagnosed with PCNSL.

关键词： Rituximab primary central nervous system lymphoma pemetrexed fotemustine WBRT

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A Phase Ⅱ Study of fotemustine Plus Dacarbazine with Dendritic Cell Vaccines as First-Line Therapy for Chinese Patients with Advanced Acral Lentiginous Melanoma

引用

Chinese Journal of Cancer Research 2009年第1期21卷 13-19页

作者： Lu Si Zhi-hong Chi Xiang-qing Yuan Chuan-liang Cui Xi-nan Sheng Jun Guo Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education） Renal Cancer and Melanoma Center Peking University School of Oncology Beijing Cancer Hospital ＆ Institute Beijing 100142 China

Objective： To investigate fotemustine plus dacarbazine （DTIC） with dendritic cell （DC） vaccines on patients with advanced acral lentiginous melanoma （ALM）. fotemustine is a cytotoxic alkylating agent with a remarkable antitumor activity as single agent but also in association with （DTIC）. DC is the strongest antigen presenting cell which could induce durable clinical responses. Methods： This was a single-center study. Between July 2003 and June 2006, twenty-eight chemotherapy-naive patients of advanced ALM received fotemustine 100 mg/m^2, dr, 12, DTIC 400 mg/d d2-6, DC vaccines subcutaneously dT, 9, 13 repeated every 28 days. Ten HLA-A02＋24＋ patients received vaccines pulsed with melanoma antigen derived peptides, melanoma antigen recognized by T-cells 1 （Mart-i） and S-100. Eighteen patients received DC loaded with allogeneic melanoma lysate. The primary end-point was progression free survival （PFS）. Secondary end-points were overall survival （OS）, overall response rate （ORR） and toxicity. Tumor assessment was performed every 8 weeks and evaluated according to response evaluation criteria in solid tumors （RECIST）. Results： The 15 men and 13 women had a median age of 51 years. 16 patients had stage Mlc disease and 11/16 had liver metastasis. Patients received an average of 3.82±1.25 cycles. Follow-up for the 18 surviving patients ranged from 7-41 months with a median of 12 months. Median PFS was 8.5 months （95% CI： 7.86-15.21） with 12 patients remaining progression free. Only 10 patients died. Median OS was 12 months （95% CI： 10.33-18.24）. ORR （CR＋PR） was 35.7% including 3 complete response （CR） and 7 partial response （PR）. Six patients had disease stable. A total of 19 Grade Ⅲ/Ⅳ toxicities were observed including thrombocytopenia （n=8）, neutropenia （n=5）, fatigue （n=6） and hypersensitivity reaction （n=1）. One patient died of Grade IV thrombocytopenia. Conclusion： fotemustine and dacarbazine plus DC vaccines are safe and tolerable to Chinese ALM patients. The regi

关键词： fotemustine Dacarbazine Dendritic cell Melanoma

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Complete response with fotemustine and bevacizumab after early progression following radiotherapy and temozolomide treatment in patient with glioblastoma multiforme

引用

Journal of Cancer Metastasis and Treatment 2015年第1期1卷 36-38页

作者： Ovidio Fernández Calvo María Eva Pérez López Jesús García Gómez Department of Medical Oncology Ourense University Hospital32005 OurenseSpain

Glioblastoma multiforme is the most common type of primary central nervous system tumor and is noted for its short survival and poor response to chemotherapeutic ***,the relapse rate is very high,and there is no reference drug for second-line *** this study,a patient was treated with the Soffi etti *** induction phase was fotemustine 75 mg/m^(2) at day 1 and day 8 and bevacizumab 10 mg/kg at day 1 and day *** maintenance phase was fotemustine 75 mg/m^(2) and bevacizumab 10 mg/kg every 3 weeks for two ***-up magnetic resonance imaging showed post-surgical changes at the left occipital level,without contrast enhancement,and toxic left leuko-encephalopathy post-treatment without mass effect and with no evidence of tumor *** patient then was maintained with bevacizumab monotherapy until it was withdrawn when pulmonary thromboembolism *** tumor regrowth,fotemustine was started again as maintenance *** patient achieved stabilization of his disease until his death due to thromboembolic and infectious complications.

关键词： Bevacizumab brain tumor fotemustine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

抗肿瘤新药fotemustine的药理和临床

引用

国外医学（肿瘤学分册） 1991年第4期18卷 233-235页

作者：于盛海孔祥林徐大江山东省医学科学院药物研究所

fotemustine是一种新的亚硝脲类抗肿瘤药物。于1989年11月在法国上市。经动物实验和临床研究证实,本品对多种肿瘤有效,尤其是对恶性黑色素瘤疗效显著。本文就近年来的研究情况对其药效学、药代动力学及临床研究进行了综述。

关键词： fotemustine 药理抗癌药

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

单剂fotemustine在非小细胞性肺癌化疗中的Ⅱ期试验研究

引用

国际肿瘤学杂志 1994年第5期 307-308页

作者：王凤菊

综合考虑以顺铂为基础的联合化疗后的临床疗效及由此引起的生活质量变化,以顺铂为基础的联合化疗方案对于非小细胞性肺癌(NSCLC)并无太多益处。有鉴于此,作者自1990年应用foetmustine单剂治疗NSCLC,并进行系统的Ⅱ期临床研究。 87例不... 详细信息

综合考虑以顺铂为基础的联合化疗后的临床疗效及由此引起的生活质量变化,以顺铂为基础的联合化疗方案对于非小细胞性肺癌(NSCLC)并无太多益处。有鉴于此,作者自1990年应用foetmustine单剂治疗NSCLC,并进行系统的Ⅱ期临床研究。 87例不能手术切除的NSCLC患者列入本研究。其中可供系统分析者77例。60％的病例曾接受不同药物及方案的化疗,74％患者有不等期别的转移,其中22例为脑转移(12例该部

关键词：小细胞性肺癌化疗方案 fotemustine NSCLC 单剂

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

fotemustine用作播散性恶性黑色素瘤脑转移的化疗

引用

癌症 1993年第1期 94-94页

作者：刘兰祥

恶性黑色素瘤脑转移预后很差,若不治疗,中数生存3—4周。恶性黑色素瘤脑转移的全身化疗极少应用,由于大多数药物缺乏疗效,脑转移经常被排除在治疗方案之外,故临床试验很少。而新的亚硝脲类—福氮芥(fotemustine)对播散恶性黑色素瘤脑转... 详细信息

恶性黑色素瘤脑转移预后很差,若不治疗,中数生存3—4周。恶性黑色素瘤脑转移的全身化疗极少应用,由于大多数药物缺乏疗效,脑转移经常被排除在治疗方案之外,故临床试验很少。而新的亚硝脲类—福氮芥(fotemustine)对播散恶性黑色素瘤脑转移治疗有效,对脑转移也有令人鼓舞的疗效,已开始Ⅱ期研究。

关键词：恶性黑色素瘤脑转移 fotemustine 生存期

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

恶性胶质瘤术后fotemustine化疗的疗效和毒性评估

引用

世界医学杂志 1999年第12期3卷 16-19页

作者：韩小弟赵继宗北京天坛医院神经外科

４０例手术后确认为恶性胶质瘤患者进行了Ｆｏｔｅｍｕｓｔｉｎｅ化疗，方案为每周一次静脉给药，剂量１００ｍｇ／ｍ＾２，共３周，休息５周后，进行维持期治疗，每３周一次剂量仍为１００ｍｇ／ｍ＾２。定期随访并复查脑ＣＴ／ＭＲＩ... 详细信息

４０例手术后确认为恶性胶质瘤患者进行了Ｆｏｔｅｍｕｓｔｉｎｅ化疗，方案为每周一次静脉给药，剂量１００ｍｇ／ｍ＾２，共３周，休息５周后，进行维持期治疗，每３周一次剂量仍为１００ｍｇ／ｍ＾２。定期随访并复查脑ＣＴ／ＭＲＩ，１２周结果，２人完全缓解，９人部分缓解，２２人病情稳定，７人病情恶化；３０月随访，其中死亡１０人，有３０例仍生存。毒性反应有骨髓抑制和胃肠反应，轻度肝功损害，均可停药后自行恢复。

关键词：胶质瘤术后化疗疗效毒性 fotemustine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：